In brief
Purdue Pharma's anticipated sentence of $225 million marks a significant step in resolving its liability related to the opioid crisis. This penalty, tied to a previous agreement in 2020, would allow the company to finalize its settlement of extensive lawsuits, with Sackler family members expected to contribute up to $7 billion to aid in addressing the addiction epidemic. While many victims support the settlement, some argue it falls short of true justice and continue to call for individual prosecutions.
A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.
The penalty was agreed to in a 2020 pact to resolve federal civil and criminal probes it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits.
After years of legal twists and turns, the settlement was approved by another judge last year and could take effect May 1. It requires members of the Sackler family who own the company to pay up to $7 billion to state, local and Native American tribal governments, some individual victims, and others.
Here’s a look at the situation.
The sentence was years in the making
Purdue pleaded guilty to three federal criminal charges in November 2020.
The Stamford, Connecticut-based company admitted that it did not have an effective program to keep its prescription painkillers from being diverted to the black market. It also admitted to paying doctors to promote the drugs.
While Purdue produced a fraction of the opioid pills that flooded the market, critics highlight its role in the crisis. Richard Sackler, a top executive, infamously called for a “blizzard of prescriptions” in 1996.
While Purdue's $225 million forfeiture is significant, the government has agreed to forgo billions in penalties in exchange for the settlement framework.
Broader Settlement Implications
Members of the Sackler family are expected to contribute up to $7 billion over 15 years, targeting the opioid crisis. This settlement ties into a larger collective effort involving more than $50 billion from various drugmakers and healthcare entities aimed at curbing addiction.
Critics remain skeptical, asserting that the deal does not provide adequate justice for victims. Many are urging the Justice Department to pursue individual criminal charges against family members involved.
The family's past financial gains from Purdue, totaling approximately $10.7 billion from 2008 to 2018, complicate perceptions of accountability moving forward.
As Purdue prepares to be replaced by Knoa Pharma, which will be run for public benefit, the future direction remains uncertain, particularly for victims seeking stronger forms of justice.
